Helicos Delisted from Nasdaq

Helicos Biosciences, the Cambridge, MA-based developer of gene sequencing instruments, has been delisted from the NASDAQ stock market, after noting in a regulatory filing that it was unlikely to meet listing requirements “due to the state of its finances and near-term business prospects.” Last month, Helicos named Ivan Trifunovich as its new CEO, and expanded its patent litigation strategy, accusing not just Menlo Park, CA-based Pacific Biosciences, but also San Diego-based Illumina and Carlsbad, CA-based Life Technologies of infringing on its patents.

Trending on Xconomy